<SEC-DOCUMENT>0001144204-13-026843.txt : 20130507
<SEC-HEADER>0001144204-13-026843.hdr.sgml : 20130507
<ACCEPTANCE-DATETIME>20130507164228
ACCESSION NUMBER:		0001144204-13-026843
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130507
DATE AS OF CHANGE:		20130507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		13820637

	BUSINESS ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v344175_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): <FONT STYLE="color: black">May 7, 2013</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="color: black">&nbsp;</FONT></B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Novavax, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Delaware</B> </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>0-26770</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>22-2816046</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">of incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">File Number) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 47%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>9920 Belward Campus Drive, Rockville, MD</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>20850</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #000033; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 7, 2013, Novavax, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing its financial results for the three months ended March 31, 2013 and conducted a previously announced,
publicly available conference call to discuss those results as well as to provide an update on the status of the Company's business
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K and Exhibit 99.1
attached hereto shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in"><B>Item 9.01.</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Exhibits</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 83%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press Release of the Company dated <FONT STYLE="color: black">May 7, 2013</FONT>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: black">May 7, 2013 </FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Novavax, Inc.</FONT><BR>
</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John A. Herrmann III, J.D.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">John A. Herrmann III, J.D.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Vice President, General Counsel &amp; Corporate Secretary</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;Index</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press Release of the Company dated <FONT STYLE="color: black">May 7, 2013</FONT>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v344175_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Contact:</TD><TD>Frederick W. Driscoll</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>VP, Chief Financial Officer and Treasurer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>Novavax, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>240-268-2000</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Novavax Reports First-Quarter 2013 Financial
Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Highlights</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Phase II RSV clinical trial data achieve protocol specified-objectives of safety and immunogenicity.</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Novel malaria vaccine candidate in India honored by the Vaccine World Summit India 2013 conference for having the &ldquo;Most
Promising Vaccine for Emerging Diseases in India.&rdquo;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Positive U.S. inter-governmental-agency panel review to continue influenza vaccine-development contract.</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Strong financial position with cash of $45.4 million providing two-years of operations. </I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD (May 7, 2013)&ndash;/GlobeNewswire/-Novavax,
Inc. (Nasdaq: NVAX) today announced </B>its financial results for the first quarter ended March 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company reported a net loss of $10.0
million, or $0.07 per share, for the first quarter of 2013, compared to a net loss of $7.3 million, or $0.06 per share, for the
first quarter of 2012. Novavax had revenue in the first quarter of 2013 of $3.8 million as compared to $4.6 million for the same
period in 2012. The decrease in revenue is primarily due to the higher level of clinical trial activity in the three months ended
March 31, 2012 associated with the company&rsquo;s seasonal and pandemic influenza programs, as compared to the corresponding period
in 2013 when no similar clinical trials were initiated. In conjunction with the decrease in revenue, the cost of revenue was $1.7
million in the first quarter of 2013 as compared to $3.8 million for the same period in 2012, which decrease is also primarily
related to the levels of activity associated with the company&rsquo;s influenza clinical trials previously mentioned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $9.4 million in the first quarter of 2013, compared to $5.3 million for the same period in 2012, due primarily to increased
costs relating to the initiation of the company&rsquo;s RSV clinical trials and higher employee-related costs. General and administrative
expenses decreased to $2.7 million in the first quarter of 2013 as compared to $3.0 million for the same period in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2013, the company had $45.4
million in cash and cash equivalents and investments compared to $50.3 million as of December 31, 2012. Net cash used in operating
activities for the first quarter of 2013 was $10.6 million compared to $4.2 million for the same period in 2012, a $6.4 million
increase from the prior year. The increase in cash usage from the prior year was due to higher influenza-related billable activity
associated with clinical trials in 2012 as compared to 2013. In addition, the increase was also associated with higher research
and development spending including the company&rsquo;s RSV clinical trials and increased employee-related costs. Cash usage may
fluctuate from period to period due to the timing of initiation and payments of clinical-related activities. The company expects
to ultimately initiate later-stage seasonal and pandemic influenza clinical trials upon completion of its process development enhancements,
which should have a positive impact on cash usage in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Highlighting a very eventful quarter
were the impressive results we reported last month from the Phase II clinical trial of our RSV vaccine candidate, which has the
potential to become a new standard of preventive care if later-stage studies are successful,&rdquo; said Stanley C. Erck, President
and Chief Executive Officer of Novavax. &ldquo;The vaccine induced clinically meaningful immunity against RSV infection with no
apparent safety concerns, suggesting it may protect infants through maternal immunization &ndash; an important consideration in
preventing severe respiratory disease due to RSV. In the meantime, we are continuing our work in collaboration with the U.S. Department
of Health and Human Services&rsquo; Office of Biomedical Advanced Research and Development Authority (BARDA) to develop seasonal
and pandemic influenza vaccines and prepare for later-stage clinical trials and are making important progress in both programs.
We shall continue to manage our financial resources carefully as we execute these development programs and look forward to reporting
on our clinical and corporate progress later this year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Highlights during and since the First Quarter of 2013:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In April 2013, we announced that top-line data from the Phase II dose-ranging clinical trial of
our respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age accomplished the clinical trial&rsquo;s protocol-specified
objectives and support progression to the next stage of advanced clinical testing. The clinical trial represents an important step
towards establishing the safety and immunogenicity of this vaccine candidate for use in a maternal immunization strategy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Also in April 2013, we appointed Amy B. Fix, Vice President of Regulatory Affairs, with responsibility
for directing regulatory strategy and coordinating the company&rsquo;s interactions with regulatory agencies that oversee the development
and commercialization of our vaccine product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In March 2013, our collaboration with CPL Biologicals and the International Centre for Genetic
Engineering and Biotechnology to develop a novel malaria vaccine in India, was honored by the Vaccine World Summit India 2013 conference
for having the &ldquo;Most Promising Vaccine for Emerging Diseases in India.&rdquo; This was one of five inaugural awards honoring
achievements in India&rsquo;s vaccine industry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In January 2013, BARDA decided to continue to support our contract to develop seasonal influenza
and pandemic (H5N1) influenza vaccine candidates following an inter-governmental-agency panel review of our vaccine-development
contract with BARDA in late 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference Call </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Novavax&rsquo; management will host its
quarterly conference call today at 10:00 a.m. EDT. The live conference call will be accessible on Novavax&rsquo; website at www.novavax.com
under &ldquo;Investor Info/Events&rdquo; or by telephone at 1 (877) 212-6076 (domestic) or 1 (707) 287-9331 (international). A
replay of the webcast will be available on the Novavax website for 60 days after the call and a replay of the conference call will
be available beginning today at 1:00 pm through July 6, 2013. To access the replay of the conference call, dial 1 (855) 859-2056
(domestic) or 1 (404) 537-3406 (international) and enter passcode 55111197.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Novavax </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage
biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant
nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat
diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections.
Novavax is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved
in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH. Together, these organizations support Novavax&rsquo; worldwide commercialization strategy and have the global reach
to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company&rsquo;s
website, <FONT STYLE="color: Blue"><U>www.novavax.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Statements herein relating to the future
of Novavax and its ongoing development of its vaccine products are forward-looking statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed
or implied by such statements. These risks and uncertainties include those identified under the heading &ldquo;Risk Factors&rdquo;
in the Novavax Annual Report on Form 10-K for the year ended December 31, 2012, and filed with the Securities and Exchange Commission
(SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation
to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>###</I></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; color: Red"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="6" STYLE="font-size: 10pt; text-align: center"><B>NOVAVAX, INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="6" STYLE="font-size: 10pt; text-align: center"><B>CONDENSED STATEMENTS OF OPERATIONS</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="6" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(in thousands, except per share information)</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(unaudited)</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 68%; font-size: 10pt; padding-bottom: 1pt">Revenue</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">3,833</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,642</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Costs and expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">Cost of revenue</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,712</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,786</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">9,432</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,338</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,694</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,985</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total costs and expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,838</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,109</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(10,005</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,467</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest income (expense), net</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">26</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>&#8213;</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">101</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations before income tax</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(9,979</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,336</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">17</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(9,996</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7,336</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.07</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Basic and diluted weighted average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt">number of common shares outstanding</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">148,448</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">120,558</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SELECTED BALANCE SHEET DATA</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, <BR>2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>
2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; padding-left: 0.9pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">9,023</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">17,399</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Investments</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">36,373</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,945</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.9pt">Total current assets</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">51,722</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,408</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.9pt">Working capital</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">42,469</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,733</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.9pt">Total assets</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">98,704</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">102,345</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.9pt">Total notes payable and capital lease obligation</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,961</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,205</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.9pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">77,568</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80,240</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>###</I></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``F`/(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#\J#^U[^UZ
M/^;MOVK/_$E/C8?Y>.:_H0_X("?\%./'=K\:]9_9!_:3^*OC3Q[HWQMO9/$'
MP3\:_%'QMKWC36O#_P`5=*TE(]4^'$GB?QCJ&KZLNA?$7P[ID%WX2TEM5M].
MT[QWX<DTC1]/N]=^)SK7\]7[)OACP[XV_:S_`&4O!7C#1[3Q#X0\9_M0_LY^
M$/%WAZ_#FP\0>%/%'QG\%:'XDT&^$;QR&QUG1;^^TR\$;I(;:ZEV,K[2/7?V
M[/V3OB!_P3T_:]\7_!Q=9\0V*^#]<T?XF?`3XF6MS+8:YJ_P_N=7EUCX9>.=
M-U:VAL9(/&/A/5='G\/:_J-C;62V7Q$\&:Y=:1&-,72[F?\`O#BG)N&N(:>+
MX+Q%'"8+,\QRJKF&6XF.&HPE2J86M""KT)PC[1SPE9X>>(HQ2]OA:M2"<H>V
MY/XIX<SGB+(IX;BZCB,7C,!EV9T\!CL/+$3G&I'$T'/V-6,Y.$8XFBJ\*-:2
M<:.)A3<K.5)3_P!$W]M35=4T+]CC]K37-#U/4M$US1OV8_CYJNC:UHU_=Z5K
M&C:MIOPI\67NG:II.J:?-;W^FZGI]Y#!=V&H65Q!=V5U#%<VTT4T:.O\+_\`
MP2;_`&E_VE_&O_!1G]D#POXT_:2_:(\9>%]<^(^H6NM^&/&'QT^*OBGPWK5J
MGP\\9W<=MJ^@:]XNU#2-3MX[NWM[I(+ZRN(EN((9E021(R_T]?"+]N?2/V^O
M^".W[2_Q5N9-/L_BQX5_96_:%^'OQY\.60$"Z1\4-$^"7B>74-:L;'8JVOAG
MQ[IESIWCGPQ'!+?6VG6.NR^%YM1N=9\,ZPL/\CG_``1V_P"4FG[%?_93=2_]
M5IXYK\>\.\DEE_"7BIE^;8&C',,NPV88:LJU*%2=&K0R?'KFHU)1OR.455HU
M864XN%:F_>4C]7X[SA8WBCPUQF68RK]0S'$X+$0]E5G3A5I5<SRYQ56G"27.
MHR<*M.:;B^:E/9H_O=_;L_;3^&7[!7[//B3X]_$R"\UH6][:^%?`/@72;NUL
MM=^)/Q'UBWOKGP_X,TF[O8YK:P2>UTS5=;\0ZU+;WB^'O"6AZ_KR:=JL^GPZ
M7>?P7?M/_P#!6O\`;Y_:Y\3W1UWXV>-?AMX3U;4ELO#_`,&_V?\`6?$/PX\*
M01:C/#8Z?H%V_A6^MO&OQ)OKV5[2%U\:ZYXA34-6DWZ)HNBPS6ND6WZC_P#!
MS_\`%#5]4_:-_9F^"AGE30/`_P`$M=^*ZV<;O'!=Z]\4?'6K>#'O;N,.([FY
MT[3?A#]FTV:5&FL(=6U>.V>--4O%E\I_X-N/V?O!_P`5/VQOB1\6O&.D66NR
M?LZ_"VQUGP19W\7FP:3\1/B/KTV@Z5XP@C)V/J?A_P`+Z!XTL-*>9)%L;OQ"
MNK6ZPZKINF7EKW<"9!D'"7A[B/$'-LKHYOF4\/5Q>'AB(TJL<-3EBG@,NPV%
M]K"4,/4Q5>5*IB,6H3JPA7Y(WA2<*G!QIGF><4\=4.!\LS&KE>74\12PM>>'
MG.F\1/ZK''8[$8CV<HRQ%/#T54AA\-*<*4YTE4ERSJ*=/XE\/?\`!'?_`(*K
M_$[1(/'5M^R;\2[B#4H1>PS_`!%^(?PI\">-)\@2+]L\*_%/XG>&O'VGW;'G
M[-K>BZ?>>>Q0P^8\A/C7_"U/^"B'_!/?XEQ>#[CX@?M-_LQ>/M$6WU>+P/KG
MB'Q/I_AC5[`3S6UIK`\#:_/K/PK^)'A=[NVN[.SU-M%\5^%;FYM+VS@GFEM[
MN%/].3`//)SSU/.?4=.>_'-?B%_P<#_`3P?\6/\`@G9\0_B1J>DV4OCW]G37
M/!_Q(^'_`(A>*)-2TNTUCQGX8\%?$/0TU`1->#0O$'@O6[Z[OM%29-/U#Q+X
M?\'ZM>0RW7A_3I;?@X>\9\7G^>9?DG$N09#7RC-<9A\OA"AA:\Y86IC*L<-A
MYUJ>-Q&,P^*HQE4C"O%4*+]E*=2'P^QGW9[X28;(LGQ^<\/9[G5'-,MPM;'3
ME6Q%&,:]/"TW7K1HSP>'PF(P]9PA4E2G*M74I\M.:2G*K'SG_@CM_P`%E9OV
MX;V?]GG]H>P\-^%OVF=`\.W.N>'/$'AV(Z-X2^.'AO0XXQKM[I>AW$]R/#WQ
M)T&W>'5/$WA6PO)]*US2$U3QCX0M-)T?2?$'ASPM^+7_``71M?VJOV2OVWM7
MUGP-^TE^TQX8^#7[1F@Q_%;X?:5X=^/7QAT'PMX=\36LL&B?%GP/H>F:?XTM
MK"RBTCQ(VF>-TTW3K6WTS1]&^)N@Z1IZ);V(@@_'3]C?XFZU\&/VN/V8/BEH
M%W<6>H>#?CY\*;ZY-K(T4M]X?U'QEI6@^,M",B`NMOXF\%ZOX@\,Z@J`F;3]
M9NH2")2&_N*_X+U?LE?\-*_L(^,?&7AW2_MOQ*_9?NKKXY^%7@CC-_J'A#1;
M":T^+_AA9]DEU):WGP_DU#Q?;Z3:))+K7BOP'X2LEC#%)(O0S#*LE\-_$[)*
M^&P]"GPYQ7AZV!Q.#K4X5:.`Q=3$4HN>'=5N-/#TL34RW$2D[NC1K8NE3Y:?
M)%<.`S/-^/?#C-Z5;$5JG$'#%6GB\/BJ-2=*MC</3HRG&-9TG>IB*N'IX_#J
M%E[:K3PM6IS5&ZC^/?\`@V__`&S?&WQF^'OQ\_9V^+_Q#\8?$3X@?#;Q/I'Q
M4\%^(?B+XQUOQEXJU+X<>.K.+0=?T.#6/$E_JFMWNF^!?&OA^/4)GO;V1;3_
M`(6AIEE9_P"B0)#;?TUY!'U'&?\`#^=?YKG_``2._::'[*?[?_P"^(&H:DVG
M>"?&VNM\#OB7,+B.VLV\#_%VXL/#]O?ZI=2_NH=%\)^/8?`GQ!U25PRBQ\(2
MXVG$B?Z#/[7'[0FA_LG_`+-'QO\`VB/$"VEQ;_";X>:[XFTS2KR5X8?$7BQ(
M1IO@?PCYT95HI_&'C74?#WA:U?S(PMSK$+&6)094^`\7^%:F6\<QCEN%7L.)
M(X3$8&A1IJ$%CJDX8'%86G&,8QYY8F,,5RQ32^NQBY+:/V_A7Q-#,.#92Q^)
MO5X?=>AC*]:4I3^I4H2Q5#$U9-N34<.YT>9^]+ZK*4KMN4OXO?\`@MS_`,%!
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M'4O%$VG:8)%N-3MU;_3AU74_A]\#_ACJ6LZG-HWP_P#A-\'_``%>:IJ-SY7V
M+P]X&^'/P]\/275W.(;:.3[+HOAGPSI,D@B@B8PV-AY<43L%4_5>+?U'AKAW
MA7@+*Z%&>,>%PV)S"M1H0>)KTL,E0I7Y8>TE+,LSCB<4HQ]]2P<8)<M2*?SG
MA?+'<19_Q)QKF%:O'!+$5\/@*-6O+ZO0J8CEKU;0<E32R_`*AAN=WIM8JI/X
MJ;E'^?G_`(.'_P!O;Q%\`/A+X"_9<^#OC37?!GQB^-EQ!XW\8>)_!GB'4_#?
MB_P1\&/">L(;+^S-=T*^TS7O#^H_$[QUIJ:'8:CI]VL=]X4\%_$G1KHQC4+9
MF_D8O?VH/VU;'2='UK4/VH/VP+/0_$O]K)X?UBZ_:%^.]MI>O#0[J+3]<&C:
MA+XUCMM2.CWL\-EJ?V*6;[!=RQV]R8IF5#UO[3/QL^*O_!1G]M+Q5\1]*T34
M;[QQ^T%\3M`\"?!OX?7=RHET#P[J&J6/@?X-?#YY(I);"PDT_3)='_X2O4;,
M0Z9<^)[_`,5>+9HXFU.]=OZG/^"JW_!+CPIX2_X)*_"CP?\`"33%U?QC_P`$
M\_#%QXWMM9M;,6^H^-/"&M1)??M2ZM-;M=31:>_B_5VF^/6M6UJ)F;4_!$6C
MZ<L45VL+?9Y-_J_X9Y;P5PWFV%PE;-N)<?*>;8BK3HSGA*N(H1@I5)U(_P`#
M#XVKEN74Y2E&G*E2QF*B^:%2$OD,UGGOB%F'%_$.4XS%4<KX>P4:>64:,ZE.
M.,AAJ[E:*A.SK5\+3S#'S4%*I&I4PN%:M*FX_>O_``1<_;8F_;0_8K\(WGB_
M7'UCXV_!&6W^#WQDN+^Z:XUK7]4T+3K>7PA\1]0,]S-?7TOQ$\'/IFJZWK<L
M-M:7_P`0K/Q]I^GHT.CMC\Z/^#CGP9\?_AWX<^"/[67P.^-'QR^'7AZQOY/@
MA\8/#_PS^+GQ+\$^']NKR:EXE^%GC>\T+P?XBT?18;I-6'B[P7X@\27L$NIZ
MO/K_`,-M#,WD:79Q+^%W_!%3]M1?V-OVU_"(\4ZRNG_!?]H$:5\&/BJ;JY,.
MDZ1=ZMJA/PM^(=Z7GM[.#_A"?&U^--U'6-1E-GH/@+QMX_U(H\J0U_>9^UK^
MSMX9_:P_9M^,_P"SEXL:&WTWXK>!-6\-66J30?:AX:\4H8=6\#^,X;;>B7%[
MX(\:Z7X?\7:?$^Z-[W18%=)$9HW_`#+B7+Z7AEXH8/,XX>$L@QV)^OTJ4J*J
M45EV/FZ&:82--P]G[7`5*E:>%I6;ITU@:LK<]C]'X>S"IXA^'6*P'UF4<]P>
M'6"J58UG"J\=@H0K9=BJE3F4U#'0I4H8BJ[*<GC(P?NNW\?7_!!+]O?XOV/[
M<MM\%OC?\:OBM\2O!W[1/@77?"'AR+XI?$[QEX]M?#OQ1\'6]SXY\'W^FS^-
MM>UI-%76_#^F^//"4UMIGV.?7]>UWPG:227$UI8VTG]QO.,XYQT]_2O\H72M
M2^*/[-OQGT[5XK-_"/QL_9X^+=M?-I5Z2_\`PC?Q5^#7C99KC1M1",HN+?3_
M`!?X;DTS48\F*\M$N(F#PSLK?ZE?P6^+?A3X[?![X7?&[P9.S^#OBU\/_"7Q
M'\//.R">VT?QCHECKMI9Z@J8%MJ&FQ7XL=5MI`DEE?VMU;7*12P2(O1XZ\/8
M?`9ME7$&`ITHX+.L)]7J/#1C[%XO!1ING53IQ4+8G!5J"I6;Y_JM274YO!?/
M<1C<LS/),?5K5,;E6*5:FL1*4JT<+BKQG1?/>=\/BZ-9S3MR/$PA9/0_FF_X
M.1/VV?'WPON?V>OV7O@U\2?''PW\6ZFFJ_'CXEZ[\./&7B;P%XGB\,1#5O`?
MPS\/R:_X4U/2M3N-!\2ZR/B-K&KZ0UTEN;[P1X6O)DN`T:Q<M_P;D^&/VB_C
M3XR^-G[47QF^.GQ^^(7P\^'UG!\&?AQX=^(/QF^)?C7PGJWQ%\0V^F^*/'OB
M*30?$_BR_P!/EU'P+X1/A31M)N9K&\M)3\2M;9/)U+1(98?YW/V_OVCK_P#;
M0_;5^.OQM\/)?^(M(\=?$$^%?@]I6FPW%W=:G\.?"8M?`7PGM-$TL&26._\`
M&&C:5IGB2;2;;S/-\5>+-4$7G27):3_0L_X)^_LM6'[&?[(/P/\`V>HEM)/$
M7@[PE#??$;4K)A-!KGQ6\5W-SXI^)6K073(D]UI\GC#5]6LO#S7)EFL_"UEH
M6DI*UKIULJ>KQC2PG`OA7D7#?U?#QS_B&*ECJTJ4/K<*;=+'YI>;CS)T)8C!
MY0N]&4G"2E3FSS.$Z^)XS\2<ZSWZSB'DF1U'3P=*%:K]5K5(PG@<OM!-4W&O
M"CB<TD[W554XRC*$K1XC_@IS^V/:?L,?L<?$_P"-MI/9?\+%O+:+X>?!'3KU
M8;B/5/C'XQ@O+;PI,]C<HUOJFG^#[2TUGXC^(M+ED@.H^%?!6NV4,HNI[=6_
MST[3]I_]M>YT/4_$5M^U'^V%>Z#H-_H6D:]X@C_:&^.EQINE:MXH@U^Y\.6>
MLZC%XU-K87_B./PKXGFTF&[>!]4.AZN;02M97"I^J'_!P7^VFO[1/[7H^`_A
M'5/M'PI_9+&K^#KAK6YSIVO_`!QU?[)_PM?5I3&T2W`\$+I^D?"ZSAU"W:XT
M/Q!X=^(DVGW+:?XFD,OZ\_L`_P#!)S1/%G_!&[XC?"SQYIEGHWQC_;D\*VOQ
MH@US5K<Q77@35+"W@U[]E*VOI8$_M./2_":V.@>/?$VA/#;:K::CX_\`B%X3
MF/ERR!O1X5ADWAEP3E>=\08&A7S/BO-<O<H5Z=.=7#99.<9*2C4IJ<8X7+'6
MQLXV4OK6*IX6K*%X(X>)IYMXA<99GD^18VMA\!PSE>.<:M"K*-+$YG3BH.#E
M3GRMXC'>RP:F]L-A:M:";NEE?\&Z7[?'BWXT>%/BG^R7\:O'GB;QY\2OAY)<
M_%GX8^*?'?B;6/%7BSQ)\+]?U&WL?&OAZ\U[7[C4]9U63X=^.]2TW4;:ZU;5
MI[C^Q/B7IVBZ7%%I/A`1Q?3'_!:S]C#]I3XK_#?_`(:3_8Z^+_Q^\(?%SX4:
M%/\`\)W\(?A1\8/BAX.TOXP?#;3!/?7%YX?\(>$_%&GZ;>_%OP4LE[J&D1Z9
MIT>M_$'PZ;OP>5U[Q%IW@#3H_P"+3]F#X]?$3]A_]JGX<?&VUT+5M/\`&OP,
M^(E]8>/?A_=F*SU34-+L[G4?!'Q@^%VJ17):TMM3U/0;CQ/X522]CGAT+Q$+
M'6DB-[HUH\?^G_X#\<>%?B=X(\&_$GP)K-KXB\$?$'PKX?\`''@OQ#9&3['K
MOA7Q5I5IKOA[6+7S8XIA!J6E7UG>QK+%'*BS*DB)(I`^<\2LMK\!\;8#BW)*
M&&>7YM?%>PE2A5R^>)@Z<<RP-6E%>SEA\;!T\5"2:?M*]6IA^66&C./O^'N8
MT>-N#L;PSG%7$1QV6I89UU5G3S".'J<TL#C(56U6CB,+4C4P]7=<M&G'$<RK
MS@_\YK]B'_@JO^T[^RO^T+X'^+OBWXS_`!O^./PN8GP]\4OAGX\^*WC;XBV'
MB7X=Z[<V3:S?>%-.\=^)=4TC2_'_`(<-K;>(O!NKVS:5<W.HZ<_A74=8M?"W
MB?Q)#<_W+?M4?\%#_@1^S=^Q@_[:%AXATOXC>"?%WAS1KKX$6.BZA]C/QD\8
M>--,GU#P!X7TJ6\MC?:?%J,-O=ZOXNN)=,FU7P7X2T/Q;K-_HTUUX>N=-;^8
MG_@O_P#\$S?#/[/7BNW_`&U/@K_8N@?#/XS>//[`^*OPX:\T_2W\-?&+Q':Z
MOX@3Q=\/["66`ZMX?^(4>E:WJ?BSPOI<4^I^%/%-I?\`BBQM[[PIXBU=?`/\
M\.L_$OX@>(/`/@7X7Z]XTUW5?AQ\+M2\9ZS\.O!>J:RB^&/!6I_$:\T[4O&]
MUHD5_-!8Z/'XDU32K35-3-S<Q:;;ZD^I:LOV*?5]=NK_`._Q7!O"WBM2X:XM
MRUK+*,:T:.?8.E2A3JU\-ATYU<!4=*,8QQF'Q$5AXXI)>VP6)]LFXTL-3?PV
M&XMXF\-*N?\`"^9.68UI1]MDN+J5'4A0KUU&-/&1]I.4I82O1_>RPUTZ6,I.
MFU[]>9]S_"7XR?\`!2K]O+]IRP^'_P`./VDOVA[WXL_&WQCJVN7MMX<^.'Q>
M\"_#'P+IUY>G4O$_B:ZT7PQXI_LCP!\*?`&G7&]-/TK3YFL=*M=+\,>';'6_
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M%,=DF`GF>>8K$XK/<U7M<33Q&(J5H8"E.7M?J\;R<'B)SESXNJDN6:6'IVA3
ME*J4445^6GZ4?Y:W[$__`">S^Q;_`-GA_LK?^K\^']?W!_\`!</_`()_2?MI
M?LNW/C3X=Z!)JO[1/[.8UOQU\-K;3K::ZUGQUX2N+>!_B-\)+2&$32W=[XGT
MS3+'Q#X/M(;9[RZ^('A3P[HMO=:?IGB/7Y+C^<[]E_\`X(H?\%,?AO\`M0_L
MQ_$CQG^SM8:3X-^'7[2/P#^('C#58_C1\#-1DTKPEX'^+?@_Q3XGU2/3M.^(
MMUJ6HOIVAZ5?WJZ?IUI=:A>F`6UC;7%U+%"_][#$;F<'N2"/3.0?\*_H?Q8X
MOPM#BOA//>&<XR_'XG**5>JZF7XVAC*4;UZ/M,+B98:K.,88J@JE&I"34I4I
MSLNI^#^&/"6*J<-<3Y+Q)E>.P-#-:U""IXS#5,-5E!8=N&(H*O32<\/65.K3
MFHRC"M3C=.S1_F#?L6?MC>)/V6Y_CUHEI<7>I_"K]J#]G7XI_`WXF>'[5I)H
M[F?Q1\/_`!?I/PN\>6=L;BV@DU;P'XO\19%S*+EAX&\4_$"QT^TFU35[&:+U
M;_@CPI7_`(*;?L7*>J_$_5`>_3X;>.N]?JK_`,%+_P#@A#^TUKG[6/CKXC_L
M3?"G1_&WP;^+4DOQ%O\`0(O'GPZ\!#X:_$77K^[F\=^%=/TWQMXJ\/O=^&=5
MU<-XS\.2:-&^G:*GB2_\(066F:=X:TK[=SG_``3@_P""/O\`P41^`'[=/[,_
MQG^+7P$L?"WPV^'?CS4=;\7^((OB[\&=?DTK3)O!/BO2(KA-&\/>/=4UO4"V
MHZG8P>1INGW4X$QE,8BCD=/TO&\8<$9CPMQ%F^#SC)L)F/$/#6)CB<!6S'`T
MLREBZ>5XO#8?"U\*ZL:\\;3E5^IWY&ZL*5"-.].--O\`/L%PEQG@.(\@R[%9
M5F>*RW(.(:,L-C:.!Q%3!QPM7,L)7KUZ=>,)16&G[/ZTTY6HRJUN;WG,]?\`
M^#H'X$:[;>._V8_VG[#3[JY\,:IX5\0?L_\`BO5$BS::)KVB:MJ?Q'^'MG<R
MABV_Q/8>(?B:]KN5(XV\)RH[M)=VZG\_/^"$/[:?PZ_8_P#VP=9T[XR>(K#P
M;\*?V@?`L7PXU3QMK%Q'8^'?!GCS2M=M-;^'>N>+M5E;R-&\)7+2^)_"NJ:Y
M=HNFZ#?^*-&US7K[2/#.FZ[JMG_=E\??@-\+?VF_A%XV^!WQH\+6OC'X<>/M
M+73-?T:XEFM9T>WNK?4=*UK1]2M62^T7Q'X>U>RL=<\.:[ITL.H:-K5A9:C9
MRI-;KG^,;]JK_@V^_:W^&>O:KJ7[+.O>&?VE?AS+=RMH6AZUXA\.?#3XRZ59
M2O+)#9>(+;Q//X?^&'B*2PM_*M;CQ+HOB[P[)K=V)+F#P#H$#K:)^=<"<9<+
MYUP17\/N+,='*91H5\)A<?7DJ="OAIXCZ[A:JQ52,L/0Q6`Q#BHQQ+ITZM/#
MT.5U)NK;[KC3A'B+*>,*/'/"^!>:+VU'$XG`THNK5I5H8>.#KP>'@U5K8;&T
M+J4L/[2I3J5:K=.$(PD_[D[*ZMM1M+:_TZ>&^L+RV@O+&^LY4N;.]M+F)9K:
MZM+J%G@N;:XA=)8+B&22*:)TDC=D96/\Z/\`P<._MN?##X?_`+*WB+]CO0/%
M.D:Y\<_CCJG@J+Q'X3T?4+>\U?X<_#+PUXIT+Q_JGB/QA;0&4Z&WC";P[I7A
M#PWI&J_9+_Q#I^O:[K>D07%EX;U&ZM?YJ]+_`."?/_!7GX;6<W@SPQ^SW^V%
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MD?\`X)V?`K7OVDOVXOV8/A3H>GRW]O=?%_P;XS\9N@80:=\-/AEK=GX_^(FH
MWET8Y+>R#^%?#^HZ5I<UV%BN_$>JZ'I,(FOM3L[:;_3ONK>WO89[6\MX;JSN
MXY8+NTN8TFM[FVG4I/;3PR*T4UO/$S13PRHT<L3-'(C(S*?RZ_X)I?\`!*WX
M-_\`!.7PEK5YHVK3?%'X\>.K"WTWXA_&G6M(@T:>;1+6Y2\@\#^`O#B7>J?\
M(1X#6_AM]6U*P_M?6-=\6:Y;V6I^*==O[70O!^C>%/U*QQCMC%?!^*O&V%XS
MS^A/+8U%E64X>6$P5:K&5.IBZM2K[7$XQ4IVG1IU'&A2HTYQC4]G0C5G&$ZL
MJ</MO#+@_$\(Y)6AF#I_VIF>(CB<73IR52&&ITZ2IX?"NI'W*LZ:E5J5)P;B
MJE:5.,I1IQG/_,%_X*(_LG/^QI^U[\<_V=5M;N#P7HGB&;Q!\*Y[@W#-?_!S
MQVC>(/A^(;ZX"3ZE-X<TB[F\!ZWJH2..[\5^#_$/E8,3!/UR_P""H?\`P4SN
M/VF_^":/[`/POLM=^U?$'XQ:*_Q!_::6"\1+]M9_9^U&_P#A5]FUS34P;?1_
MB;\9--\1?$WP_!,#=10_#_1+LS-;W=O-?_K5_P`%W/\`@F-\6OVU+/X&?%[]
MF;P3IWC'XV^`+O5_AQXTT2;Q'X3\'3>(/A'K4%YXDT74IO$'C/6]"T>63X>>
M-;2_ATG1H[R.\NK?XH^);]?M`TR.%/YTF_X(-?\`!5AE(C_9HTA)678DEQ\=
MO@,($.3L:=H?B1-,MNKNSR^3#-(J&1HH99"$;]MR'B;@_BO*."<[XDSW)\#G
MO"]:I4KT<QS#!X>O/&0PL\'4K.G7KTZG)B*U++\YIU:::C5H4Z7+=34?Q_.>
M'.+.&LSXPRCA[)<RQF2\14*5*G5P6#Q-:A3PM6M3Q,*49T:<H\V&I5<=E52G
M)QE[&K*K>*E!O]>_^#9/]DLVFE?&G]MGQ3II6XUJ>;X!?!V6YAE0GP_IMQI?
MB3XO>);(21M;75KK'B2W\&^#]-U"W=+C3[WP1XZTN3?#J#;?6?\`@Y)_;5_X
M5[\'O!G[$O@K5#!XQ^.J6?C[XNO:3A+K2?@CX9UL_P#"/:%/A(Y[8_%'XBZ'
M)&MS:73QS^&_AKXS\/:O:/8>*(#)^^7[*_[/WA;]D_\`9N^#O[/?@R(7FC_"
M7P)I'AF6^M[:.QN/%/B)!+J/C+Q?/;23""VU3QQXPO\`7O%NH1&6*UCU+7+D
M(;>WPL?\8O[7O_!++_@L-^U]^T?\7_VD/&?[+]M;:G\2O%%UJ.B>&W^/G[/,
MX\(^"=*MX=$^'_@:WFA^)T.GN?#'@_3=&TB_OK2.VM]:UN+5O$D\0OM9O9)/
MSOAO,\FXP\3LRXLXAS7+,NRK+*\<1E='-<=AL$\1]7E]6R6G2I8JI33="G26
M88MTK*GC(PYX_P"T:_>Y[E><<+^'.`X8R'+,PQV9YA0^KYE5R[#5\5[#VZ^L
M9M5J5:$)**K5*CP.'4[.>&G+D?\`LY^,/[.?[37BC]D;XV^#OCQ\/4^'=S\1
M_`2ZW-X27XD:3-XBT32;_7]"U#PW<ZY'HEMKN@M/JUKI&KZG#I5Q<W4UM87%
MXU]%:M?VUC<V?ZKWO_!R/^WYJ=E>:;JFJ?LJ:GINHVMQ8:EINH?"2ZNK#4;"
M\A>WO+"^M)OB.\-U9WEO));W5O,KQ3P2R1R(58@_V:_\$_OV2="_8M_9(^#G
M[/L%OI5]XC\,>'$UGXE:[;00W$?B7XK>*Y7\0?$+6HKR6VBN[S31X@OKG2/#
M#7V^ZL?!ND>'-&\PV^F0(GV5]CM.UG9@]O\`1+?K_P!^JZ>(?%KA'-<TQ%7%
M\`8'/8X:=3!X+,\7F$:=7$8'#XBK+#58TGEM:5"%7G>(C256;@ZK3D[:<>1^
M%W%679;0I83CC%Y*L3"EB\5EV&R^<Z='%UZ%!5Z;J+,J7MG#D5)U'2@I<BE&
M$4W?_(WCGTK4K>>.S&G2:?()H#96,TMS8VUM+O5=.B-U>:A=O!!;N+>+[=>W
M=V\*(UQ<SRL\K_Z,7_!%S]MB3]M#]BWPC=^+];.J_&WX'26GP<^,4M[=^?K.
MNZAH&FV[^#?B1?&XE>^O6^(O@TZ;J>LZU+#;V%Y\0+#Q]IFFH8=$DQ\S_P#!
M=/\`X)C_`!*_;9\*?!KXH_LU>#=,\3_'KX8:QJ/@S6_#LFN>$_!@\6?"'Q3#
M/JC,^O>*-0T327U'P#XQL;6_T'3KK5+56TOQIX[EM_M-\]G:R_"7_!'?]@O_
M`(*B_L&_M:V?B?Q_^SZFG?`+XL>'KGX?_&[['\9?@GK)TBTLTO-8\`_$*#0-
M(^)$]_K&I^"/%#3:<T5I:WU[;^#/&OCO^RM-U+5[BQM9/9XSXCX7\1_#Z.8S
MQ^59/Q#E-7$8O"Y1CLTPBQT:E&3HXC"4I5EAZN)AF.#5+$4)4Z*4\3'#T9VE
M2G;S.$N'^)N`>.)8..#S'-LAS&E1PN*S/"9?76%DJT83PV+J1I.O3H2P.+=6
MA7A*I)TZ$ZU5-QG#F^-O^#BO]DX?!7]L;2/VAO#6G"V\"?M6>'3J^JFUA1+3
M3_C+\.K31_#WCFW:.WBCAL$\4^%;OP)XLMWG/VKQ!XDF^(&IDS26M])'U7[+
MW_!31OA7_P`$.?VG/@.=?>W^,G@GQLO[/GP?'F317\?P_P#VK1XK\4'6+745
M=;M-6\$Z9HW[2>I:&\*/!I`\+^!])BGM8KFWCL/Z9/\`@K3^Q?J7[<W[%?C_
M`.%7@W3K+4/B]X2O]*^*_P`$8[Z]M--BN?B/X/COH?\`A'AJ6I75EI>GOX[\
M&ZKXN\`0ZAK%]9:/I=WXHM-8U*[MK737FC_CB_X<-_\`!53_`*-ETT=>?^%Z
M?`'OZ@?$W!(!QU/IG%;\&Y]PKQ7P1DN3\6YUE>!QG#&;Y?.E',L=A,+4Q5'*
MJD:F#DH8NM3]K0K9=6GE=>4;M.G.H^5R498\4Y!Q-PWQCG.9\+91C\;@N(<K
MQE.J\!AJ]:.'K9G3=/%Q<J$)<E:EF%*GFE'FM_$C33Y5)KMO^"!O[)1_:1_;
MM\,^/M;TL7?PT_91L-/^,_B!YK<S:;/\11=W6G?`W0971EDM=0B\6V&I_$S2
M'RL<G_"IKRUE#).%;^QC_@IM^V19_L,?L=?%#XX6LUFWQ#N;6+X?_!+2[X0S
M1ZO\8_&4%W;>$W>RN0(-3T_PE:VNL?$;Q)ICRPM?^%/!6O6MO)]KE@5_"?\`
M@C#^PCXF_83_`&26\/?%;0K#1/CY\5O&NM?$/XMV-IJ>C>(/^$?^SO\`\(UX
M#\%V_B/0KF^T[5+'0O!^DV>M7$=CJ%[IUIXL\6^+UL+FY@G^U7'YN_\`!;[]
MC3_@I+^W9\=/`?AKX&_`G^WOV</@IX6W>%M4NOBY\'?#2^-OB;XUM[.\\;^+
M9=!\0>/]&UN&S\/Z7::#X$\/1Z]HUI?6-]IWCK4])>71/%\,]U\=G>;91X@>
M*E)9EFV787A;*IK#QQ.-QV'PN#Q>`RR7M<13HU:\Z=.N\VQ]2I3A*FU4E@:L
M)MVP]SZO),JS?@CPVJ1R_+<7B.)LS@L2\+A<+4KXK#8W'QA3I3JTX1<H?V;@
MHTI5%-<D<73=.W[X_C5DUZ&TU*'6_$L]EXBGFUA-8U8>-+R[U"V\6WC:@-3U
M2+Q1<&_M-3U>+Q!,9E\0L-2MM0U&*]O#]N@N)Q<K^WZ?\'*7_!0>)$CBU_\`
M9<BCC54BBC^%-ZD<4:*%CBC4?$D!8XT`1%`PJ@`#BOZ'O^"&G_!-?Q]^P_\`
M"WXK>./VA_".E>'OV@_C!XHL])FT2+6O#/C#_A#_`(4>"(YT\-:3'K?AV[UO
M1DU+Q5XEU3Q%XI\0+HVLW$%YI,?@.RU:*+5O#CV]M^[7V.S_`.?.S/\`VZ6_
M_P`:KZ/C+Q6X1Q&;5<OJ\(9?Q7@LJDZ&!S.KF5)8>?/3P[Q+P=-9?B81I>VI
M*BJE.M*->&'IU%:')%?.\)>&/%>'RR&.H\68[AG&9G&-;&Y?#`59UX.%2K[!
M8JL\?AIRK*G4E4E3G27L9UIT[MJ4I?Y1WQM^.^K?M*?&7XB?&WQ7%X#L?&WQ
M-UT^+?%VG?#O3#H7AE]?N+*QL]9UNQT&75]:N+.Z\1ZA;2^(O$4QU"=+[Q-J
MVK:F%M_[0%O'_6G_`,&^W_!0_P`$:/\`LM_&C]GOX]>-M*\*67[)6B:Y\9O#
M'BGQ)?"&WB_9TUG4I]1\8P.5CN=1OE^%?Q#U2=9'!DD.C_%#P!X3\.:;-_9*
MVY_7#_@K3^Q)=?MR?L8>._AAX)TC2[CXQ>#;[3_BK\$!<3:?I"77Q$\*17D#
M^&&U2]FL=,L%\?\`A#4O%/@..^UF\M=%TO4?$6FZ]JEQ#;:.98_X[X_^"$/_
M``5;B2YCB_9LM(HKRW%K>11?'KX"Q1WEJM[9ZBEM>1Q_$X)=6\>H:=I]^D$X
MDA6^L;.\"?:;2VEB]N/$G!'B;P;/)\UQN6\&5<!C<)3P>&QF9X%U,)#!1I>Q
MQ&!EB_J2K4JV!J8C`RO37LI2FY.3C!R\U<.<9^'W%D<TRS"9AQ;'&X3$U,;B
ML-@:\*>+J8R=1U:6*A1EB72JTL6J&+O[67M8QC90YI)>3_\`!3?_`(*#^._^
M"CG[1(\56MCXATKX.^#KNY\(_LZ_"@V\UWK5MI>JWEM9R>)];T;3#>)?_%?X
MGWMOILFIZ=I27HT>SC\.>`-'EUJ30[CQ!XDR_P!N'_@F1^T9^P3X-^`?C?XP
MV-K>Z'\;/"%G/K%YHENTUC\+OBY+#J.L:K\$?%&IV]YJ.FWGB73_``G%9:O9
M:W9W46D>*;VP\>67AJ&_TWP-<ZWJG[W_`/!'+_@B5\6_@K\=[G]I3]MWP%HO
MAK5_A1/;'X#_``T_X2?P;X]CO?'%W:R23_%K7;KPAKGB'0;-/`UO(MG\/]-N
M[J?55\97EYXR>TT.[\&>#]2UC^D;]IW]FWX8?M;_``-^(/[/WQ@TJ74O!'Q"
MT9K"YN+)X8-:\-ZS:S1ZAX=\9^&+R>"YAL/%/A'7;:P\0:!=SVUU:#4+&.#4
MK._TNYOM/N_/S7Q5R7@_.,@X<X3AAL7PID]&G1S6MA/9XA8I8B#YOJ6(A*,*
MM;"NH\;B*RDOK>-E4H3G!1J3GU9;X:9QQ7E.>9]Q-4Q6&XDS2<ZF4T,6IT'A
M70G>/UNA.*J4J6)</JM"C)7PV$5.M",N:$(_S8?\$`/^"IRZI:Z!^P!^T+XF
M?^V-,LA8_LK>.M=NS*NKZ'IENTC_``#UG4+F4S1ZKX<L8Y+OX12S,]KJ'A:V
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M8J=VH1K\E'Z+POXSQ$ZD^"N(I3HYSE;J8;`2Q+:K8BCA%RSP-1R;<L3A(1?L
MI.WML+!6YITG.K^T-%%%?@MUW7WH_;1-H_IU/^-+113`3`]_S/\`C1@9SW]R
M3_.BBBR[?U_27W`+2;1SQUS^O7Z9]J**.WEMY>G8`VJ.P_(=N?Y\_7FC`';T
M_3I^7;T[444;[ZA9=A:***`$(!Z_Y^OK^-&T>_YG_&BB@!:3`]_S/^/-%%`"
M@`=****`#`_S_G\O3M28'_ZR3_.BB@!<#_/^?_U<TF![_F?\:**++L`8'I_G
M_/\`7UHP/\D_X\^WI110`N!_G_/^<#THHHH`*3`]_P`S_C110```=*7K110!
M^*W_``6^_8(\&?M;_LH>+?BS:-I?AKXX?LO>#?&7Q0\%^-+F.=8]9\#^'M%N
M?$?Q#^&'B$VD%Q-=:/XBTG2)=5\-3F"2Y\/>.=,T>[MKFWT+5O%^GZU_"%\`
M?CS\3_V9/C#X`^//P:U__A'?B'\/=7CU?1+BXCFN='U6TGB:UUKPIXITR"ZL
MWUCPAXKTF:ZT/Q)I2W=K<3Z;>2RZ;?:9J]OIVJV117]9^`]6IF?"6<Y3F$OK
MF6T,QGA*6#Q*C5H0PN,PE.>*PZC-.]&M.<YRI-N"E.<HI.<F_P"7_&JE3R[B
MG)LSP$?JF/K8&.*JXJ@Y4ZL\3@\6X8:NW%I>UI0A"$9I*3A"$9-QA%+^\WX;
M_P#!;']G3QS\._`7C;5/AM\;_#^I^,?!?A;Q3J.@Z=I7@#7]/T2_\0Z'8ZM=
MZ18Z[=>.-`N=:L]-N+R2SM=6N-"T6?48(4O)M)TZ29K.$HHK\(QN0Y52QF+I
M4\-.-.GB:].$?K6,?+"%6<8J[Q#;LDE=MM]6V?MF$S?,*F%PM2==2G4P]"<Y
5.AATY2G3I2D]*22NY-Z))=+65O_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
